Table 12 Staging and treatment data

Prior radiation

Goyal, 2017

272 (46.2%)

130 (62.5%)

< 0.001

Kozin, 2016

12 (46.2%)

22 (48.9%)

0.824

Howard, 2016

6 (67%)

7 (44%)

0.071

3 (50%)

Gieger, 2016

98.0%

94.6%

0.356

Jing, 2014

15 (68.2%)^a

23 (85.2%)^a

ND

Granzow, 2013

4 (25%)

7 (39%)

0.5

Paydarfar, 2011

4 (12%)^a

0

0.14

Mallet, 2009

3 (12%)

15 (33%)

0.09

Chepeha, 2004

37 (52%)

56 (52%)

NS

Tsue, 1997

8 (28%)

13 (54%)

0.05

Kroll, 1997

49 (33.8%)

9 (28.1%)

0.5360

Prior chemotherapy

Kozin, 2016

7 (26.9%)

11 (25%)

0.859

Jing, 2014

7 (31.8%)^a

4 (14.8%)^a

ND

Granzow, 2013

1 (6%)

6 (33%)

0.09

Paydarfar, 2011

1 (3%)^a

1 (3.7%)^a

0.14

Tsue, 1997

0

1 (4%)

ND

T1

Zhang X, 2014

1 (50%)

1 (50%)

0.369

Jing, 2014

7 (31.3%)^a

8 (29.6%)^a

ND

Deganello, 2013

0

4 (20%)^a

< 0.01

Fang, 2013

0

3 (15%)^a

ND

0

ND

Paydarfar, 2011

1 (3.0%)^a

2 (7.4%)^a

0.38

Hsing, 2011

46 (42.2%)

63 (57.8%)

0.904

Mallet, 2009

32% (8/25)

44% (20/45)

0.44

Chien, 2005

0

9 (56.25%)^a

NS

Funk, 2002

1 (4.8%)

1 (4.8%)

NS

Tsue, 1997

11 (37.93%)^a

6 (25%)^a

ND

T2

Zhang X, 2014

10 (76.9%)

3 (23.1%)

0.369

Jing, 2014

6 (27.3%)^a

10 (37.0%)^a

ND

Deganello, 2013

7 (43.8%)^a

5 (25%)^a

< 0.01

Fang, 2013

7 (35%)^a

12 (50%)^a

ND

4 (33.33%)^a

Paydarfar, 2011

15 (45.45%)^a

17 (62.96%)^a

0.38

Hsing, 2011

90 (35.3%)

165 (64.7%)

0.621

Chien, 2005

6 (54.5%)^a

7 (43.75%)^a

NS

Funk, 2002

1 (4.8%)

0

NS

T3

Zhang X, 2014

37 (66.1%)

19 (33.9%)

0.369

Jing, 2014

7 (31.8%)^a

2 (7.4%)^a

ND

Deganello, 2013

8 (50%)

8 (40%)

< 0.01

Fang, 2013

3 (15%)

6 (25%)

ND

2 (16.7%)

Paydarfar, 2011

11 (33.33%)^a

6 (22.22%)^a

0.38

Hsing, 2011

38 (40.0%)

57 (60.0%)

0.621

Chien, 2005

5 (45.45%)^a

0

NS

Funk, 2002

5 (23.8%)

5 (23.8%)

NS

T4

Zhang X, 2014

31 (79.5%)

8 (20.5%)

0.369

Jing, 2014

1 (4.5%)^a

7 (25.9%)^a

ND

Deganello, 2013

1 (6.25%)

3 (15%)

< 0.01

Fang, 2013

9 (45%)

12.5%

ND

6 (50%)

Paydarfar, 2011

6 (18.18%)^a

2 (7.4%)^a

0.38

Hsing, 2011

12 (37.5%)

20 (62.5%)

0.621

Chien, 2005

0

0

NS

Funk, 2002

14 (66.6%)

15 (71.4%)

NS

T1-T2

Li, 2016

10 (41.67%)

8 (47.06%)

0.981

Forner, 2016

5 (41.7%)^a

6 (66.6%)^a

ND

Mallet, 2009

8 (32%)

20 (44%)

0.44

Tsue, 1997

11 (37.93%)^a

6 (25%)^a

ND

T3-T4

Li, 2016

14(58.33%)

9(52.94%)

0.981

Forner, 2016

7 (58.3%)^a

3 (33.3%)^a

ND

Mallet, 2009

17 (68%)

25 (56%)

0.44

Tsue, 1997

17 (58.6%)^a

18 (75%)^a

ND

Stage I-II

Chepeha, 2004

16 (23%)

23 (21%)

NS

Stage III-IV

Chepeha, 2004

85 (79%)

55 (77%)

NS

Surg +chemoradio

Li, 2016

8(33.33%)

7(41.18%)

0.854

Fang, 2013

4 (20%)

5 (20.83%)

ND

2 (16.67%)

ND

Hsing, 2011

25 (39.7%)

38 (60.3%)

0.687

de Bree, 2007

40 (100%)

37 (92.5%)

ND

Chepeha, 2004

27 (38%)

46 (43%)

NS

Paydarfar, 2011

16 (48.48%)^a

12 (44.44%)^a

0.03

Surg + radio

Zhang X, 2014

41 (51.9%)

17 (54.84%)

0.781

Paydarfar, 2011

13 (39.39%)^a

5 (18.5%)^a

0.3

Hsing, 2011

25 (39.7%)

38 (60.3%)

0.687

Chepeha, 2004

27 (38%)

46 (43%)

NS

Tumor stage

Kroll, 1997

2.80 ± 0.94

3.14 ± 0.83

0.1106

Tumor reccurence

Kroll, 1997

44(32.6%)

11 (33.3%)

0.9350